Schechter Investment Advisors LLC Boosts Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Schechter Investment Advisors LLC boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 6.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 13,705 shares of the biotechnology company’s stock after acquiring an additional 816 shares during the period. Schechter Investment Advisors LLC’s holdings in Exelixis were worth $456,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Principal Securities Inc. boosted its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Exelixis in the fourth quarter worth about $32,000. Kestra Investment Management LLC acquired a new position in Exelixis during the fourth quarter worth about $39,000. UMB Bank n.a. boosted its position in Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 553 shares during the last quarter. Finally, V Square Quantitative Management LLC grew its stake in Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 425 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research reports. JMP Securities reissued a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a research note on Thursday, January 23rd. Stifel Nicolaus lifted their price objective on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. Stephens restated an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Finally, Piper Sandler boosted their price target on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.24.

Exelixis Stock Up 0.9 %

NASDAQ:EXEL opened at $38.65 on Thursday. The company has a market cap of $10.82 billion, a price-to-earnings ratio of 21.84, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $39.30. The company has a fifty day simple moving average of $34.81 and a two-hundred day simple moving average of $31.91.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Buying and Selling

In other news, CFO Christopher J. Senner sold 29,314 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares of the company’s stock, valued at approximately $28,174,996.98. This represents a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock worth $5,177,234 over the last 90 days. 2.85% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.